Neuren Pharmaceuticals Limited (NEU.AX)
Neuren Pharmaceuticals Limited
697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 9092 0480
https://www.neurenpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 420.83k | N/A | N/A |
| Ms. Lauren Frazer C.A. | CFO & Company Secretary | N/A | N/A | N/A |
| Mr. Lawrence Glass BA (Biology) | Chief Science Officer | N/A | N/A | N/A |
| Mr. Gerry Zhao | Vice President of Corporate Development | N/A | N/A | N/A |
| Dr. Liza A. Squires M.D. | Chief Medical Officer | N/A | N/A | N/A |
Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Corporate governance
Neuren Pharmaceuticals Limited’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 1; Compensation: 5.
